Most pharmaceutical assets are not lost in a single event. They drift. A handoff that does not get recorded cleanly. A location update that does not happen at the right time. A temperature reading that is captured but never reviewed. The asset is technically somewhere. The operations team just cannot confirm exactly where it is or what condition it is in, and the gap between recorded data and physical reality widens a little with every shift.
That is what asset drift looks like in pharmaceutical supply chains. It is the gradual erosion of certainty about high-value assets, and in pharma it carries a different weight than it does in most industries. The same drift that creates an efficiency problem elsewhere can create a compliance problem, a recovery problem, and ultimately a trust problem for the operations leaders responsible for product integrity.
Pharmaceutical supply chain visibility, done well, is what lets teams detect drift before it becomes loss. This article looks at what asset drift actually is, why it is especially costly in pharma, and how leaders are closing the gaps.
What Asset Drift Looks Like in Pharmaceutical Operations
Asset drift is the gradual erosion of certainty about an asset’s location, status, and condition. It rarely shows up as a single failure. It accumulates across handoffs, shifts, and facility transitions until the team realizes the records and the physical reality have separated.
In pharmaceutical operations, drift tends to show up in three places. Reusable cold-chain containers that should be at a distribution center but cannot be reliably confirmed. High-value samples or batches with handoffs that did not get logged consistently between facilities. Returnable totes, racks, and shipping assets with chain-of-custody gaps between 3PL partners and internal sites. Each individual gap looks small. Collectively, they erode the operational confidence that pharma operations depend on.
Why Pharmaceutical Environments Make Drift Especially Costly
Pharma is more exposed to asset drift than most industries, and the reasons stack up quickly.
Asset values are high. Reusable cold-chain shippers, specialized totes, and clinical sample containers can each carry significant replacement costs, and the products they carry are more valuable still. The cold-chain and time-sensitive nature of pharma workflows compounds any uncertainty: a temperature excursion that goes undetected for hours is a different problem than one that gets flagged in real time. Compliance frameworks (DSCSA, GDP, FDA, EU requirements) require chain-of-custody clarity that asset drift directly undermines.
Deloitte’s case work with biopharmaceutical clients has documented the pattern. In one global biopharma engagement, siloed source systems and limited supply chain visibility led to inefficiencies that frequently required time-consuming, hands-on intervention to resolve. The pattern is common across the industry: when visibility breaks, the operational and compliance cost of recovering from drift is significantly higher than the cost of preventing it.
The Five Signals That Drift Is Already Happening
So how do operations leaders know whether drift is already accumulating in their network? Five signals tend to show up before drift becomes loss.
- Inconsistent handoff records. Different systems showing different last-known locations for the same asset. The discrepancies are usually small, but the underlying gap is real.
- Dwell time anomalies. Assets sitting longer than expected at a node without a clear explanation. When the system cannot account for the dwell, it usually means the data has fallen out of sync with the physical movement.
- Reactive recovery. Teams searching for assets rather than allocating them. The shift from forward-looking deployment to backward-looking recovery is one of the clearest signals that drift is accumulating.
- Cold-chain exceptions clearing without root cause. A pattern of brief temperature excursions getting logged and forgotten. The exceptions themselves may be minor; the pattern is what matters.
- Expanding buffers. Operations carrying more reusable inventory than the design assumed, to compensate for assets that cannot be located. The buffer is the symptom; the visibility gap is the cause.
What Visibility Has to Deliver in Pharmaceutical Operations
Not every visibility platform delivers what pharma operations actually need. To detect drift early and document chain of custody at audit grade, the system has to clear a specific bar.
- Continuous chain-of-custody. Every handoff logged, every location confirmed, every transition documented. The data has to follow the asset from origin to destination without gaps.
- Condition data alongside location. Especially for cold-chain workflows where temperature, humidity, and shock data are as important as where the asset is.
- Cross-facility and cross-partner coverage. Including 3PL partners, distribution centers, and clinical sites. Drift usually starts where the data does not cross an organizational boundary cleanly.
- Exception alerts that support compliance, not just operations. Documentation matters as much as the action. An alert that fires and gets cleared without leaving an audit trail is not enough in pharma.
How IoT-Enabled Tracking Helps Detect Drift Early
The technology to close these gaps is mature and already in use across high-stakes operations. RFID, BLE, GPS, and IoT sensor tags can be applied to high-value pharmaceutical assets, with condition data (temperature, humidity, shock) captured alongside location. Fixed readers at facility transitions and mobile validation at handoffs ensure the data follows the asset wherever it moves.
Here is what early detection looks like in practice. A reusable cold-chain container that should be on its return cycle shows dwell time exceeding the norm at a distribution partner. The system flags the anomaly with the full chain-of-custody history attached. Operations recovers the asset before the next cycle is impacted, and the audit trail is complete. The drift happened. The loss did not.
What Operational Certainty Looks Like for Pharma Operations
Surgere has spent more than two decades building this kind of supply chain visibility for high-stakes industries where physical-world data accuracy is a requirement, not a preference. The Interius platform, which is Surgere’s supply chain intelligence software, combines IoT hardware, RFID infrastructure, and an agentic AI layer called Sophia to deliver 99.9% physical-world data accuracy across more than 2,000 client locations in 28 countries.
The same hardware-validated approach that has delivered measurable results in adjacent industries (substantial annual savings, significant load time improvements, and consistent fleet-level accuracy gains) applies directly to pharmaceutical operations where chain-of-custody clarity, cold-chain integrity, and recovery speed are foundational.
Drift starts as ambiguity. It ends as loss. Visibility is what changes the ending.
Where to Start
Closing asset drift in pharma does not require a wholesale system replacement. It requires picking the right starting point and being honest about where the data most often breaks.
- Map the handoff points where chain-of-custody data is most likely to break. Usually these are the transitions between internal operations and 3PL partners, or between sites in different regions.
- Identify your highest-value or most compliance-sensitive asset classes. Reusable cold-chain shippers, clinical sample containers, and specialty totes carrying time-critical product are usually the priority.
- Choose hardware-validated tracking with condition data, not just location. Software-only tracking misses the temperature and shock context that pharma operations need.
- Build exception alerts that document, not just notify. Every alert should produce an audit-ready record. Notification alone is not enough.
Detecting drift early is one half of the conversation. Using visibility to improve readiness and asset utilization is the other. We covered that side in How Asset Visibility Turns Pharmaceutical Inventory Into Usable Capacity.
Contact Surgere to see how IoT-enabled visibility can detect asset drift in your pharmaceutical operation before it becomes loss.
